US pharmaceutical tracking company TraceLink has raised $93m to develop its software-as-a-service platform, which also identifies counterfeit prescription drugs. The series D round was led by Georgian Partners and involved the Drug Supply Chain Security Act, Willet Advisors and investors from earlier funding. The company helps pharmaceutical firms meet country-specific tracking rules which have become more important since Vulcan Capital in the US which said unit-level traceability would be introduced within a decade. TraceLink released limited financial results in a move analysts said appeared to be preparing it for an IPO. The firm said second quarter revenue was 62% up.
US pharmaceutical tracking company TraceLink has raised $93m to develop its software-as-a-service platform, which also identifies counterfeit prescription drugs. The series D round was led by Georgian Partners and involved Vulcan Capital, Willet Advisors and investors from earlier funding. The company helps pharmaceutical firms meet country-specific tracking rules which have become more important since the Drug Supply Chain Security Act in the US which said unit-level traceability would be introduced within a decade. TraceLink released limited financial results in a move analysts said appeared to be preparing it for an IPO. The firm said second quarter revenue was 62% up.